Mediwound Ltd
NASDAQ:MDWD

Watchlist Manager
Mediwound Ltd Logo
Mediwound Ltd
NASDAQ:MDWD
Watchlist
Price: 18.7 USD -3.11% Market Closed
Market Cap: 239.7m USD

Net Margin
Mediwound Ltd

-98.4%
Current
-90%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-98.4%
=
Net Income
-20.6m
/
Revenue
20.9m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
IL
Mediwound Ltd
NASDAQ:MDWD
239.8m USD
-98%
US
Eli Lilly and Co
NYSE:LLY
1T USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
491.8B USD
27%
CH
Roche Holding AG
SIX:ROG
271.4B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP
16%
US
Merck & Co Inc
NYSE:MRK
274.9B USD
30%
CH
Novartis AG
SIX:NOVN
218.8B CHF
26%
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
33%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
-126%
US
Pfizer Inc
NYSE:PFE
144.9B USD
16%
No Stocks Found

Mediwound Ltd
Glance View

Market Cap
239.8m USD
Industry
Pharmaceuticals

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

MDWD Intrinsic Value
6.82 USD
Overvaluation 64%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-98.4%
=
Net Income
-20.6m
/
Revenue
20.9m
What is the Net Margin of Mediwound Ltd?

Based on Mediwound Ltd's most recent financial statements, the company has Net Margin of -98.4%.

Back to Top